SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049234
Filing Date
2024-04-26
Accepted
2024-04-26 16:38:38
Documents
7
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A trvi_-_def_14a_2024.htm DEF 14A 739323
2 GRAPHIC img38854683_0.jpg GRAPHIC 55345
3 GRAPHIC img38854683_1.jpg GRAPHIC 20442
4 GRAPHIC img38854683_2.jpg GRAPHIC 55345
5 GRAPHIC img38854683_3.jpg GRAPHIC 20442
6 GRAPHIC img38854683_4.jpg GRAPHIC 229190
7 GRAPHIC img38854683_5.jpg GRAPHIC 130369
  Complete submission text file 0000950170-24-049234.txt   1435341
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38886 | Film No.: 24884561
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)